论文部分内容阅读
Itakura所参加的研究小组在1977年及1978年首次分别合成了生长激素释放抑制因子(Somatostatin)和胰岛素基因,并通过基因工程技术,使这些基因在大肠杆菌内得到了表达,从而在通过细菌发酵生产人类的多肽激素方面,有了重大突破。目前,美国、欧洲均成立了专业的基因工程公司,各大药厂及不少大学、研究单位均在大力研究。预期3～5年内可通过基因工程技术,使细菌发酵生产多肽激素、干扰素、肝炎疫苗等商业化。本文虽然偏重在基因的化学合成方面,但亦能使我们对这方面的工作有一个概括的了解。
The team Itakura participated in for the first time synthesized somatostatin and insulin genes in 1977 and 1978, respectively, and genetically engineered to express these genes in E. coli, There has been a major breakthrough in the production of human polypeptide hormones. At present, the United States, Europe have set up a professional genetic engineering company, major pharmaceutical companies and many universities, research units are vigorously studied. It is expected that 3 to 5 years will be able to commercialize bacterial fermentative production of peptide hormones, interferons and hepatitis vaccines through genetic engineering. Although this article focuses on the chemical synthesis of genes, it also gives us a general idea of the work in this field.